Study of chronic myeloid leukemia patients in treatment-free remission
Part of Blood & lymphatic, Cancer clinical trials.
This follow-up study looks at people with chronic myeloid leukemia (CML) who have been in deep remission and may be able to stay off treatment. It checks how long remission lasts and how their leukemia tests behave over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (age 20 or older) with chronic-phase CML
- Your leukemia genetic test shows BCR-ABL type e13a2 or e14a2 (p210)
- You have NOT previously shown resistance to nilotinib or dasatinib (second-generation tablets)
- You have taken imatinib for at least 5 straight years, or nilotinib/dasatinib for at least 4 straight years
- Your blood or bone marrow test has stayed very low (MR4.5 or undetectable) for at least 2 years, confirmed on at least 4 separate tests
- You can get a sensitive qPCR BCR-ABL test that can detect down to MR4.5
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study keeps records of people with chronic-phase CML who stopped their targeted leukemia pills (TKIs) while in a very deep remission. Researchers want to understand outcomes after stopping treatment and how often remissions are maintained.
This study looks at stopping TKI treatment (a type of targeted therapy for CML) to see if you can stay in remission without medication. It is for people with CML in chronic phase who are either newly diagnosed or on a TKI but not achieving optimal results or not tolerating the drug.
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
This trial tests a maintenance therapy called ABC (likely a combination of drugs) to see if it can keep adults with acute myeloid leukemia (AML) in remission longer after their first successful treatment. The goal is to prevent the leukemia from coming back and improve overall survival.
This study uses a very sensitive blood test (digital PCR) to look for specific genetic mutations (changes) in the BCR::ABL1 gene in people with CML. The goal is to understand why some treatments stop working, which can help doctors choose the next best medication for you.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
Hear when a new Chronic Myeloid Leukemia, BCR/ABL-Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.